School of Medicine
Showing 51-100 of 518 Results
-
Emily Chan
Associate Professor of Pathology (Clinical Pathology)
BioDr. Chan is an Associate Professor of Pathology at Stanford University. She completed her MD, PhD at New York University and Anatomic Pathology residency with subspecialty Genitourinary Pathology training at University of California-San Francisco (UCSF). She is AP board-certified. Dr. Chan has been a GU attending at UCSF for the past five years where she has successfully mentored numerous trainees in projects, publications, and career planning. Dr. Chan has co-authored more than 40 peer-reviewed research publications and has a particular interest in integrating molecular testing in diagnostic pathology, as well as recognition of prostate cancer architectural patterns than can help with prognosis and treatment decision making.
-
Howard Y. Chang, MD, PhD
Virginia and D. K. Ludwig Professor of Cancer Research, Professor of Genetics and, by courtesy, of Pathology
On Leave from 12/16/2024 To 12/15/2026Current Research and Scholarly InterestsOur research is focused on how the activities of hundreds or even thousands of genes (gene parties) are coordinated to achieve biological meaning. We have pioneered methods to predict, dissect, and control large-scale gene regulatory programs; these methods have provided insights into human development, cancer, and aging.
-
Vivek Charu
Assistant Professor of Pathology and of Medicine (Quantitative Sciences)
BioI am a physician and a biostatistician. My clinical expertise is in the diagnosis of non-neoplastic kidney and liver disease (including transplantation). My research interests center on the design of observational studies and clinical trials, the analysis of observational data, and causal inference.
-
Greg Charville, MD, PhD
Associate Professor of Pathology
BioDr. Charville has a special interest in the diagnosis of rare tumors that derive from bone and soft tissues, including muscle, fat, blood vessels, cartilage, and other connective tissues. He also specializes in the classification and study of diseases related to the gastrointestinal and hepatopancreatobiliary systems.
Dr. Charville particularly enjoys working alongside Stanford's excellent physicians-in-training to classify the most diagnostically challenging cases in collaboration with pathologists from around the world, bringing to bear cutting-edge techniques for comprehensive histologic and molecular characterization in each case. This experience serves as the inspiration for laboratory-based investigation of the molecular underpinnings of human disease, focusing on genetic and epigenetic mechanisms of neoplasia and the translation of these mechanistic insights into novel diagnostic and predictive biomarkers. -
Michael Cleary
Lindhard Family Professor of Pediatric Cancer Biology and Professor of Pathology, Emeritus
Current Research and Scholarly InterestsThe role of oncoproteins in cancer and development; molecular and cellular biology of hematologic malignancies; targeted molecular therapies of cancer.
-
Laetitia Coassolo (Voilquin)
Senior Research Scientist - Basic Life, Pathology Sponsored Projects
Current Role at StanfordI am a Senior Research Scientist in Dr. Katrin Svensson's lab. I am interested in mapping tissue-specific peptide secretion to identify orphan peptide hormones.
-
Maria Inmaculada Cobos Sillero
Associate Professor of Pathology
Current Research and Scholarly InterestsOur lab uses cellular and molecular methods, single-cell technology, and quantitative histology to study human neurodegenerative diseases. Current projects include:
- Using single-cell RNA-sequencing to understand selective vulnerability and disease progression in human Alzheimer’s disease brain
- Investigating mechanisms of tau-related neurodegeneration in human brain
- Studying the neocortical and limbic systems in Diffuse Lewy Body Disease (DLBD) at the single cell level -
Le Cong
Assistant Professor of Pathology (Pathology Research) and of Genetics
Current Research and Scholarly InterestsOur lab develops gene-editing technologies like novel CRISPR systems and large gene insertion techniques for gene&cell therapy. We also leverages these gene-editing tools for single-cell functional screening, to probe molecular mechanisms of cancer and immunological diseases. To accelerate our work, we integrate AI and machine learning to design and evolve gene-editing proteins/RNAs in silico, pushing the frontier that bridges computational and experimental biology.
-
Joanne Cornbleet
Associate Professor of Pathology at the Stanford University Medical Center, Emerita
Current Research and Scholarly InterestsAs medical director of the Hematology Laboratory, my main focus is service work, including laboratory administration, bone marrow pathology, and flow cytometry interpretation. Publications arise primarily from development or evaluation of laboratory methods or collections of unusual patient cases.
-
Helio Costa
Adjunct Clinical Assistant Professor, Pathology
BioHelio Costa, PhD, is a medical geneticist specializing in oncology, genomics, computational biology, data science, artificial intelligence, and product development. His work focuses on developing new cancer therapies and medical software to improve cancer patient care. He currently serves as Senior Medical Director and Head of Molecular Therapeutics & Drug Development at Natera and is an Adjunct Clinical Assistant Professor in the Department of Pathology at Stanford Medical School.
Dr. Costa’s research spans the entire drug development pipeline, from discovery to FDA-approved therapies. He leads efforts in developing innovative cancer treatments by integrating advanced genomics, computational biology, and AI-driven methodologies. His team focuses on the creation of targeted molecular therapeutics, using large-scale genetic data to identify novel treatment pathways and predict patient responses. In addition to drug discovery, Dr. Costa oversees the clinical trials necessary for validating these therapies, ensuring they meet rigorous standards for safety and efficacy. Furthermore, he manages the product development and commercialization process, guiding new treatments from initial research through to market-ready, FDA-approved cancer therapies.
In addition to his therapeutic work, Dr. Costa has led the development and implementation of genetic diagnostic tests and clinical algorithms used to support therapeutic decisions at Stanford Health Care. His contributions include the creation of DNA and RNA cancer diagnostic tests, as well as algorithms that analyze large-scale laboratory datasets and electronic medical records to predict patient outcomes. As a co-investigator with the NIH Clinical Genome Resource (ClinGen) Consortium, Dr. Costa oversaw developing FDA-recognized medical software used by healthcare providers, researchers, and biotech companies to assess the clinical relevance of genes and mutations.
He is the founding director of the Stanford Clinical Data Science Fellowship, where post-doctoral medical fellows engage in interdisciplinary clinical research and implement real-world health data solutions within Stanford Health Care. Dr. Costa is also an Attending Medical Geneticist for the Molecular Genetic Pathology Laboratory at Stanford Health Care, where he previously served as Assistant Lab Director.
Dr. Costa holds a BS in Genetics from the University of California, Davis, a PhD in Genetics from Stanford University School of Medicine, and completed his ABMGG Clinical Molecular Genetics and Genomics fellowship training at Stanford University School of Medicine. -
Tina Cowan
Professor of Pathology (Clinical) and, by courtesy, of Pediatrics (Genetics)
Current Research and Scholarly Interestsscreening and diagnosis of patients with inborn errors of metabolism, including newborn screening, development of new testing methods and genotype/phenotype correlations.
-
Gerald Crabtree
David Korn, MD, Professor of Pathology and Professor of Developmental Biology
Current Research and Scholarly InterestsChromatin regulation and its roles in human cancer and the development of the nervous system. Engineering new methods for studying and controlling chromatin and epigenetic regulation in living cells.
-
Ronaldo Francisco Jr
Postdoctoral Scholar, Pathology
BioI am a geneticist focused on the application of computational and statistical methods to study genetic mechanisms of disease. My research interests include (i) genomic and precision medicine; (ii) detection and analysis of genetic variants using NGS data (WGS, WES, RNA-Seq); and (iii) transcriptome and allele-specific expression.
-
John W. Day, MD, PhD
Professor of Neurology and Neurological Sciences (Adult Neurology), of Pediatrics (Genetics) and, by courtesy, of Pathology
Current Research and Scholarly InterestsOur Neuromuscular Division coordinates a comprehensive effort to conquer peripheral nerve and muscle disorders, including the muscular dystrophies, motor neuron disorders, neuromuscular junction abnormalities, and peripheral neuropathies. With patients and families foremost in mind, we have had success defining and combating these diseases, with research focused on identifying genetic causes, developing novel treatment, and maximizing patient function by optimizing current management.
-
Dr. Qiwen Deng
Postdoctoral Scholar, Pathology
BioHow fibroblasts participate in the organ fibrosis and whether targeting fibroblasts is a good strategy to reverse fibrosis is still a mystery. We have identified two important immune checkpoints, CD47 and PD-L1, are highly expressed in fibroblasts and blocking CD47 and PD-L1 reversed lung fibrosis. This is a prove of concept that targeting immune regulatory pathways could be an effective therapeutic approach to treat fibrotic diseases. In addition to identifying novel targets for the treatment of fibrosis, I am also interested in the crosstalk between fibroblasts and innate immune cells in the development of fibrosis. Combined with cutting-edge NGS approaches including single cell sequencing, spatial transcriptomics and high-dimensional CyTOF technique, we have identified several potential targets and characterized immune cells landscape in lung fibrosis. In the long run, I will focus on the validation of these targets. Specifically, I will apply gain- and loss-function approaches to investigate their role in fibrosis in vitro and in vivo.
-
Dylan Dodd
Assistant Professor of Pathology and of Microbiology and Immunology
Current Research and Scholarly InterestsHarnessing the gut microbiome to treat human disease.
